Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.00M | 2.00M | 2.00M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 2.00M | 2.00M | 2.00M | 2.00M |
| Cost of Revenue | 0.00 | 1.99M | 1.99M | 1.99M | 1.99M |
| Gross Profit | 0.00 | 13.00K | 13.00K | 13.00K | 13.00K |
| SG&A Expenses | 8.48M | 8.72M | 7.17M | 6.74M | 6.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.25M | 17.09M | 15.01M | 15.67M | 16.32M |
| Operating Income | -14.25M | -15.09M | -13.01M | -13.67M | -14.32M |
| Income Before Tax | 131.82M | 75.32M | 55.74M | -22.22M | -24.51M |
| Income Tax Expenses | 21.85M | 11.31M | 11.94M | 2.01M | 3.77M |
| Earnings from Continuing Operations | 109.97 | 64.02 | 43.81 | -24.22 | -28.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 34.00K | 34.00K | 44.00K | 61.00K | 41.00K |
| Net Income | 110.00M | 64.05M | 43.85M | -24.16M | -28.24M |
| EBIT | -14.25M | -15.09M | -13.01M | -13.67M | -14.32M |
| EBITDA | -14.13M | -14.97M | -12.89M | -13.53M | -14.15M |
| EPS Basic | 2.64 | 1.52 | 1.04 | -0.60 | -0.69 |
| Normalized Basic EPS | -0.06 | -0.19 | -0.13 | -0.14 | -0.15 |
| EPS Diluted | 2.57 | 1.47 | 0.99 | -0.62 | -0.71 |
| Normalized Diluted EPS | -0.06 | -0.19 | -0.13 | -0.14 | -0.15 |
| Average Basic Shares Outstanding | 165.18M | 165.63M | 165.48M | 164.62M | 163.84M |
| Average Diluted Shares Outstanding | 168.26M | 167.52M | 167.37M | 165.49M | 164.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 9.42% | -- | -- | -- | -- |